At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ZBIO Zenas BioPharma Inc.
Market Closed 04-11 16:00:00 EDT
7.93
+1.15
+16.96%
盘后7.86
-0.07-0.88%
18:41 EDT
| High8.03 | Low6.84 | Vol179.46K |
| Open6.94 | D1 Closing6.78 | Amplitude17.55% |
| Mkt Cap331.47M | Tradable Cap165.57M | Total Shares41.80M |
| T/O1.36M | T/O Rate0.86% | Tradable Shares20.88M |
| P/B-- | ROE-- | EPS0.00 |
| 52wk High-- | 52wk Low-- | P/E-- |
| Dividend-- | Div.Yield-- | ROA-- |
Loading ...
Zenas BioPharma appoints Haley Laken as CSO
TIPRANKS · 04-07
Zenas Biopharma Appoints Haley Laken, Ph.d., as Chief Scientific Officer
THOMSON REUTERS · 04-07
Press Release: Zenas BioPharma Appoints Haley Laken, Ph.D., as Chief Scientific Officer
Dow Jones · 04-07
North American Morning Briefing: Stock Futures Fall as Focus Shifts From Fed to Tariffs
Dow Jones · 03-21
Zenas BioPharma Gains Outperform Rating From Analyst As Key Autoimmune Trials Progress
Benzinga · 03-20
Zenas BioPharma Initiated at Outperform by Wedbush
Dow Jones · 03-20
Wedbush Initiates Zenas BioPharma at Outperform With $35 Price Target
MT Newswires Live · 03-20
Zenas BioPharma initiated with an Outperform at Wedbush
TIPRANKS · 03-20
Zenas Biopharma Appoints Lisa Von Moltke, M.d., as Head of Research and Development and Chief Medical Officer
THOMSON REUTERS · 03-17
Press Release: Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer
Dow Jones · 03-17
Is Zenas BioPharma (NASDAQ:ZBIO) In A Good Position To Invest In Growth?
Simply Wall St. · 03-13
Director Makes Bold Move with Major Stock Purchase in Zenas BioPharma!
TIPRANKS · 02-12
BRIEF-Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives
Reuters · 02-05
Zenas Biopharma- Cash Equivalents, Short-Term Investments as of Dec 31 to Fund Operating Expenses & Capex Requirements Into Q4 2026
THOMSON REUTERS · 02-05
Zenas Biopharma :Topline Results From Pivotal Phase 3 Trial in Immunoglobulin G4-Related Disease (Indigo) Expected Year-End 2025
THOMSON REUTERS · 02-05
Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases
GlobeNewswire · 02-05
Zenas BioPharma Initiated at Outperform by Wolfe Research
Dow Jones · 02-04
Wolfe Research Initiates Coverage on Zenas BioPharma With Outperform Rating, $19 Price Target
MT Newswires Live · 02-04
Zenas BioPharma initiated with an Outperform at Wolfe Research
TIPRANKS · 02-03
Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference
GlobeNewswire · 01-28
Introduction
Company Name.
Zenas BioPharma Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Issue price:
--
Invest in Global Markets with Tiger Brokers!Open App